Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × Abituzumab × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostate Cancer Metastatic 1 Colorectal Neoplasms 1

Interventions

Bevacizumab 230 Fluorouracil 218 Irinotecan 215 Oxaliplatin 212 Leucovorin 196 Capecitabine 149 Cetuximab 145 Panitumumab 70 Folfox protocol 49 regorafenib 43 Radiotherapy 38 pembrolizumab 37 IFL protocol 36 HMPL-013 36 trifluridine tipiracil drug combination 32 Nivolumab 30 Drug Therapy 25 Neoadjuvant Therapy 24 Trifluridine 18 Celecoxib 18 tislelizumab 17 sintilimab 16 XELOX 16 Trastuzumab 16 durvalumab 15 atezolizumab 15 aflibercept 15 Chemotherapy, Adjuvant 15 apatinib 14 Gemcitabine 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03688230 2020-03-18

AMELION

SFJ Pharmaceuticals, Inc.

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡